Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
Ronit Gurion, Uri Rozovski, Gilad Itchaki, et al.
Haematologica (2021) Vol. 107, Iss. 3, pp. 715-720
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review
Simon Galmiche, Liêm Binh Luong Nguyen, Éric Tartour, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 163-177
Open Access | Times Cited: 175
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf, Justin C. Laracy, Miguel‐Angel Perales, et al.
Immunity (2022) Vol. 55, Iss. 10, pp. 1779-1798
Open Access | Times Cited: 88
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
Joanne S. K. Teh, Julien Coussement, Zoe C. F. Neoh, et al.
Blood Advances (2021) Vol. 6, Iss. 7, pp. 2014-2034
Open Access | Times Cited: 70
Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients
Simeon Schietzel, Manuel Anderegg, Andreas Limacher, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002036-e002036
Open Access | Times Cited: 66
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Nico Gagelmann, Francesco Passamonti, Christine Wolschke, et al.
Haematologica (2021) Vol. 107, Iss. 8, pp. 1840-1849
Open Access | Times Cited: 65
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
Moshe Mittelman, Ori Magen, Noam Barda, et al.
Blood (2021) Vol. 139, Iss. 10, pp. 1439-1451
Open Access | Times Cited: 62
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
Christian Buske, Martin Dreyling, Alberto Álvarez‐Larrán, et al.
ESMO Open (2022) Vol. 7, Iss. 2, pp. 100403-100403
Open Access | Times Cited: 51
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Tanaya Shree, Vishnu Shankar, Julian J.K. Lohmeyer, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 2, pp. 95-102
Open Access | Times Cited: 41
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
Carlo Visco, Luigi Marcheselli, Roberto Mina, et al.
Blood Advances (2021) Vol. 6, Iss. 1, pp. 327-338
Open Access | Times Cited: 43
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies
Thomas Ollila, Rebecca Masel, John L. Reagan, et al.
Cancer (2022) Vol. 128, Iss. 18, pp. 3319-3329
Open Access | Times Cited: 34
Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies
Akio Mori, Masahiro Onozawa, Shihori Tsukamoto, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 6, pp. 691-696
Open Access | Times Cited: 23
COVID-19 vaccination in cancer patients: a narrative review
Suranjith L. Seneviratne, Pamodh Yasawardene, Widuranga Wijerathne, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 3
Open Access | Times Cited: 23
Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside
Justin C. Laracy, Mini Kamboj, Santosha A. Vardhana
Current Opinion in Infectious Diseases (2022) Vol. 35, Iss. 4, pp. 271-279
Open Access | Times Cited: 23
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma
Takashi Ishio, Shihori Tsukamoto, Emi Yokoyama, et al.
Annals of Hematology (2023) Vol. 102, Iss. 6, pp. 1421-1431
Open Access | Times Cited: 13
Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations
Francesco Passamonti, Emanuele Nicastri, Alice Di Rocco, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 3-15
Open Access | Times Cited: 18
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies
Antoni Ribas, Madhav V. Dhodapkar, Katie M. Campbell, et al.
Blood Cancer Discovery (2021) Vol. 2, Iss. 6, pp. 562-567
Open Access | Times Cited: 26
Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas
Francesco Marchesi, Fulvia Pimpinelli, Diana Giannarelli, et al.
Leukemia (2021) Vol. 36, Iss. 2, pp. 588-590
Open Access | Times Cited: 25
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 17
BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses
Irit Avivi, Efrat Luttwak, Esther Saiag, et al.
British Journal of Haematology (2022) Vol. 196, Iss. 6, pp. 1329-1333
Open Access | Times Cited: 15
Vaccination for SARS-CoV-2 in Hematological Patients
Niccolò Riccardi, Marco Falcone, Dafna Yahav
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 257-266
Open Access | Times Cited: 14
A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies
Maryam Noori, Shadi Azizi, Farhan Abbasi Varaki, et al.
International Immunopharmacology (2022) Vol. 110, pp. 109046-109046
Open Access | Times Cited: 14
Management of vaccinations in patients with non‐Hodgkin lymphoma
Michele Merli, Andrea Costantini, Silvio Tafuri, et al.
British Journal of Haematology (2024) Vol. 204, Iss. 5, pp. 1617-1634
Open Access | Times Cited: 2
COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis
Yusuke Ito, Akira Honda, Mineo Kurokawa
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, Iss. 8, pp. e691-e707
Open Access | Times Cited: 12
Current approaches for the diagnosis and management of immune thrombocytopenia
Anat Gafter‐Gvili
European Journal of Internal Medicine (2022) Vol. 108, pp. 18-24
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top